A deleterious bacterial infection can take hold when the diverse community of bacteria in the gut microbiome are killed with antibiotics.
C. diff
Postdoc Sherry Cao receives NIH Pathway to Independence Award
Xinyun (Sherry) Cao, a postdoctoral researcher in the Landick Lab, was awarded a Pathway to Independence Award (K99/R00) from the NIH.
How a narrow-spectrum antibiotic takes aim at C. diff
Most antibiotics are double-edged swords — while killing bacteria, they also decimate beneficial bacteria and change the composition of the gut microbiome. The answer to this problem might be narrow-spectrum antibiotics. UW–Madison scientists took a close look at one such antibiotic using cryo-EM. Their findings are detailed in Nature.
Venturelli R21 to provide major advance for personalized microbiome therapies
Clostridioides difficile, an antibiotic-resistant intestinal pathogen, is the leading cause of hospital-acquired infections in the United States. Treatment of a Clostridioides difficile, also known as C. difficile, infection may include courses of antibiotics or fecal transplants in which the fecal sample of a healthy donor is transplanted into a patient with C. difficile. These treatments …